Tools chosen: polymarket_direct claude_news gdelt_news earnings_data kalshi_related polymarket_related wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

This is a biotech regulatory timing question: whether Moderna/Merck will submit a BLA for intismeran autogene (mRNA-4157/V940) by June 30, 2027. The key drivers are the Phase 3 INTerpath-001 trial readout timing, any interim analysis results, company guidance on filing timing, and FDA regulatory pathway signals (breakthrough designation, accelerated approval possibility). I'll anchor on the Polymarket price, search news for trial/regulatory updates, check cross-market signals, and pull company earnings commentary.

# Current state Merck/Moderna announced positive Phase 3 INTerpath-001 interim results on 2026-08-19 (met primary/key secondary endpoints for RFS/DMFS in resected melanoma). As of late Aug 2026, the companies say they will "engage with regulatory authorities regarding filing submissions" — no BLA has yet been submitted and no specific filing date has been announced. The market closes 2027-06-30/07-01, giving ~10-11 months post-readout for submission. # Timeline of key events - 2023-02: FDA grants Breakthrough Therapy Designation to mRNA-4157/V940 (confirmed, Wikipedia). - 2024: Moderna/Merck hold preliminary FDA discussions seeking accelerated approval on Phase 2 data; FDA gives discouraging feedback, no accelerated pathway pursued (confirmed, FierceBiotech/Synapse). - 2026-06-01: 5-year KEYNOTE-942 (Phase 2b) follow-up data presented at ASCO — 49% reduction in recurrence/death risk, 59% reduction in distant metastasis/death vs. pembrolizumab alone (confirmed, Merck.com). - 2026-Q2 earnings call (~July 2026): Moderna President Stephen Hoge states positive interim readout "would obviously make the case for an accelerated review" (confirmed, FierceBiotech). - 2026-08-19: Phase 3 INTerpath-001 interim analysis meets primary (RFS) and key secondary (DMFS) endpoints; first positive Phase 3 for an individualized neoantigen/mRNA cancer therapy (confirmed, Merck.com/ASCO Post/Dermatology Times/FierceBiotech). - 2026-08-19 onward: Companies state plan to present detailed data at an upcoming medical meeting and "engage with regulatory authorities regarding filing submissions" — no BLA filed, no date given (confirmed, Dermatology Times). - Ongoing: INTerpath program expanding into bladder cancer, NSCLC, metastatic melanoma trials (Merck.com) — no signs of deprioritization. # Event Will a BLA for intismeran autogene (mRNA-4157/V940) be submitted to/accepted by FDA (or the drug approved) by June 30, 2027? # Outcomes to forecast - Yes - No # Kalshi market anchor No direct Kalshi price returned for this ticker in the research (kalshi_direct not present in raw data). Polymarket's equivalent contract trades at 87.5% YES, flat over 7 days (+0%), +1% over 30 days, range 86.5-87.5% over 13 data points, modest volume ($40.6K total). Treat Polymarket as the best available cross-market anchor in absence of direct Kalshi quote. # Sub-question answers 1. **INTerpath-001 status/readout** — Positive interim analysis announced 2026-08-19 (met primary RFS and key secondary DMFS endpoints); trial continues for OS. ClinicalTrials.gov lists primary completion ~Oct 2029 and full completion Sept 2030, but the interim analysis is being used as filing basis, not final completion (claude_news, ASCO Post, FierceBiotech). 2. **BLA filing guidance** — No specific filing date given; companies say only they will "engage with regulatory authorities regarding filing submissions" post-2026-08-19 readout (Dermatology Times). No evidence of timing slipping or accelerating beyond this qualitative statement. 3. **Interim efficacy sufficiency** — Yes, positive and "clinically meaningful" per companies; first positive Phase 3 for this drug class, viewed as filing-enabling (Merck.com, FierceBiotech). 4. **Expedited designations** — Breakthrough Therapy Designation granted Feb 2023, which can support faster review post-filing but doesn't itself trigger submission timing; a 2024 accelerated-approval bid on Phase 2 data was rejected by FDA (Wikipedia, FierceBiotech/Synapse). 5. **CMC/manufacturing hurdles** — No specific hurdles reported in current research; no mention of manufacturing/CMC delays for this individualized therapy. 6. **Earnings/pipeline commentary** — Moderna's Hoge (Q2 2026 call) said a positive interim readout would support case for accelerated review; broader coverage (Fool.com, Yahoo Finance) frames this as a key upcoming approval catalyst for Moderna, with Merck stock also up on program strength (247wallst.com). No explicit BLA date given. 7. **Polymarket/cross-market** — Polymarket prices this event at 87.5% YES, stable/slightly rising. No matching Kalshi-related markets found (searches for "cancer vaccine"/"Moderna" returned no hits); adjacent Kalshi FDA-approval markets (Verve-102, MDMA, Type 1 diabetes cure) are unrelated comparators showing 41-56% ranges, not directly informative here. # Key facts (high-confidence, factual) 1. [Merck.com/ASCO Post] Phase 3 INTerpath-001 interim results positive (RFS, DMFS) announced 2026-08-19. 2. [Dermatology Times] No BLA submission date announced; companies only "engaging with regulators" as of late Aug 2026. 3. [Wikipedia] BTD granted Feb 2023. 4. [FierceBiotech/Synapse] 2024 FDA rebuff of accelerated approval bid based on Phase 2 data. 5. [Polymarket] Current price 87.5% YES, stable. # Cross-market signals - Kalshi related: No direct/related Kalshi markets found for this specific event or company; adjacent FDA-approval markets (unrelated drugs) show 41-56% range, low relevance. - Polymarket: 87.5% YES, flat 7d, +1% 30d, thin volume (~$40K) — suggests market views submission as likely but not certain. - Sportsbook implied: N/A. # Analyst opinions and speculation - Financial media (Fool.com, Yahoo Finance, 247wallst.com) frame the melanoma vaccine as a key near-term catalyst/approval driver for both MRNA and MRK stocks, implying market expectation of forward regulatory progress, though not specifying BLA date (GDELT). - Moderna's Hoge suggested accelerated review is plausible given positive data, implying possible expedited timeline post-filing (FierceBiotech). # Directional lean per outcome - **Yes**: Positive Phase 3 interim data (Aug 2026) gives ~10-11 months before deadline; BTD in place; companies actively "engaging" regulators; Polymarket at 87.5%; strong commercial incentive to file quickly given first-in-class positioning. - **No**: No confirmed filing date; prior 2024 FDA rebuff shows regulatory caution with this novel modality; individualized neoantigen therapies have complex CMC/manufacturing (patient-specific), which could add preparation time; companies' language ("engage with regulators," "present at upcoming medical meeting") suggests pre-filing stage, not imminent submission, as of Aug 2026. # Gaps / unknowns - No direct Kalshi YES price was returned in raw data (tool output missing) — brief anchors on Polymarket (87.5%) as best available proxy. - No confirmed regulatory meeting outcomes or CMC review status post-August 2026 readout. - No specific target quarter for BLA filing disclosed by either company. - FMP earnings data calls failed (403 errors) — no additional guidance from most recent earnings transcripts available. # Calibration anchors - Polymarket YES price: 87.5% (proxy anchor in absence of direct Kalshi quote). - Precedent: BTD-holding biologics with positive pivotal data often file BLA within 6-12 months; typical timeline from positive Phase 3 readout to BLA submission for standard biologics is 6-9 months, suggesting filing plausible before mid-2027 given Aug 2026 readout, but individualized/personalized therapy CMC complexity and 2024 FDA skepticism introduce added uncertainty.

1. Both forecasts anchor almost mechanically to the Polymarket 87.5% price without independently stress-testing it; given the brief notes only ~$40.6K total volume ("thin volume"), this is a low-liquidity proxy that could be driven by a handful of traders and may not reflect true probability, yet neither forecaster discounts for this thinness beyond a token "shade slightly below." 2. Neither forecast adequately weights the 2024 precedent where FDA gave "discouraging feedback" on an accelerated pathway — this is the single most relevant regulatory-interaction data point for this exact drug/agency pair, and both treat it as a minor caveat rather than a meaningful base-rate adjustment for this specific FDA division's caution with novel neoantigen therapies. 3. The interim analysis is being used as filing basis while the trial's primary completion is listed as ~Oct 2029 (full completion Sept 2030) — neither forecaster explores the scenario where FDA requests additional maturity/follow-up data (e.g., OS trends) before accepting a BLA based solely on an interim RFS/DMFS readout, which happened with the 2024 Phase 2 rebuff for similar reasons. 4. Both forecasts treat "individualized neoantigen manufacturing/CMC complexity" as a minor residual risk, but this is a genuinely novel regulatory question (patient-specific biologic manufacturing controls) with no direct precedent cited in the brief for BLA-stage CMC review timelines — this could be a fatter tail risk than the ~13-14% No probability implies. 5. Neither model discusses what happens if the companies announce a filing date after the "engage with regulators" phase that itself falls close to or after June 30, 2027 (e.g., late 2027 filing plans) — the brief's key gap ("no specific target quarter for BLA filing disclosed") should push more mass toward No or at least widen uncertainty, yet both converge tightly around 86-87%, understating genuine uncertainty from this missing information. 6. Both forecasters are nearly identical (87% vs 86%) despite claiming independent reasoning, suggesting anchoring bias to the single Polymarket data point rather than genuinely divergent modeling — no scenario analysis (e.g., probability trees for "files by Q1 2027" vs "files Q2 2027" vs "delayed past window") is shown to justify the precision implied by these point estimates.

85% (64% confidence)

Yes: 85% No: 15%

Both forecasts converge near the 87.5% Polymarket anchor, and the fundamentals support high YES probability: positive Phase 3 interim results hitting both RFS and DMFS endpoints in August 2026 leave ~10-11 months before the deadline, comfortably within the typical 6-9 month readout-to-BLA window for a BTD-holding program with strong first-in-class commercial incentives. The red-team critique validly flags thin Polymarket liquidity (~$40K), the 2024 FDA rebuff as a division-specific caution signal, unprecedented patient-specific CMC review questions, and the absence of any announced filing quarter — these are correlated tail risks slightly understated by both forecasts. However, the interim analysis is filing-enabling per the companies, regulatory engagement is active, and the resolution criteria (submission OR acceptance OR approval) set a relatively low bar. I shade modestly below both forecasts to 0.85 to reflect the missing filing-date guidance and novel CMC uncertainty, but the critique does not identify evidence strong enough to justify a larger move against consensus.

Total pipeline time: 162.2s